Sanid. mil. 2018; 74 (4) 219 Sanidad Militar Revista de Sanidad de las Fuerzas Armadas de España Sanid. Mil. Volumen 74, número 4. ISSN: 1887-8571 Octubre-Diciembre 2018 CONTENTS EDITORIAL 221 Training of Military medical officers for military operations in the Military Medical School-Central Academy of Defense. Spain Samper Lucena E., Bartolomé Cela, E. ORIGINAL ARTICLE ARIMA models to predict the joint expense of in-flight oxygen and other gases in the Air Force. Gallego-Nicasio Moraleda JA., Rodríguez Aranda A., Mínguez Novella.J., Jiménez Pérez F. 223 SUMMARY: Introduction: contract records of gases and similar elements used by the Air Force are being signed from 1997. The management of this activity was appointed, from the very beginning, to the Air Force Pharmacy of Madrid (CEFAR-MA). However, the last divergences between the asigned economic licenses and the actual execution have been noticeable. The lack of mathematical predictive models may account for the disadjustment between the budgeted and the executed. The elaboration of statistic and economeric estimates is retained as the main basis to efficiently forward-looking through contract records of gases properly done, that is, not based on the inertial increment of historical budgets. Aims: mathematical estimates of budgetary prediction in budget allocations of contract records of gases used by the Air Force. Materials and method: gath-ering of the economic data from invoicing and payments. Billing figures have been deflated taking 2016 as the basis. For the mathematical, graphic and statistical treatment of the data the following computing apps have been used: Microsoft® Excel (2016), Eviews®10, Gretl (2017c) and Statistica v12 (StatSoft inc.). Results: different ARIMA models have been obtained, being ARIMA (3,1,0) the best in annual and quarterly result validation. Conclusions: ARIMA models allow to predict the economic allocations in the contract records of fases in the Air Force. KEYWORDS: Temporal series, ARIMA, contract records, Box-Jenkings. Development of a method for the Ochratoxin A (OTA) detection by High Resolution Liquid Chromatography with Time Mass Detector Guamán Collaguazo CE., Peraile Muñoz I., Fernández Martínez C., Cabria Ramos JC., Gil García M. 230 SUMMARY: Antecedents: Ochratoxin A (OTA) is a mycotoxin produced by certain fungi (Aspergillus y Penicillium). It can be found in several types of food, depending on both production and storage conditions. It has carcinogenic, nephrotoxic, teratogenic, immunotoxic and neurotoxic properties. It is toxic by inhalation and ingestion. Since this toxin has a high stabil-ity and its extraction is relatively simple, it represents a serious public health and safety problem. Therefore, in order to help ensure the safety of all the citizens, it is necessary to develop a fast and sensitive ochratoxin detection method. In this sense, liquid chromatography coupled to a time-of-flight mass detector (HPLC-MSD(TOF)) has revealed as a very suitable diag-nostic technique to achieve a rapid and specific detection of this mycotoxin. Aim: Development of a fast and specific method of OTA by using HPLC-MSD(TOF). Material and Methods: Thirty-six assays were tested with different chromatographic and spectrometric conditions. In all the assayed cases, HPLC 1200 and an MSD(TOF) 6210 with electrospray ionization source were used, (Agilent Technologies). Results: The chromatogram obtained showed the peak of OTA at a retention time of 1,791 ± 0,009 minutes. In its mass spectrum it is observed both the molecular ion M+H+ at 404,07986 uma and its char-acteristic isotopic profile. Conclusions: The OTA detection method optimized by HPLC-MSD(TOF) is fast and specific. This method could be suitable for the detection of other toxins, allowing the creation of a database for toxins suspected of being used as bioterrorist agents (or biological warfare agents). KEYWORDS: Mycotoxin, ochratoxin A, bioterrorist agents (or biological warfare agents), HPLC-MSD(TOF). BRIEF COMMUNICATION Pneumomediastinum and Bilateral Pneumothorax in Patients with Idiopathic Pulmonary Fibrosis Coca Benito D., Jareño Esteban J., Molina López-Nava P., Lucena Calvet P., Villegas Fernández F. 234 SUMMARY: Patients with idiopathic pulmonary fibrosis (IPF) have a higher risk of developing acute pulmonary compli-cations, including pneumothorax and spontaneus pneumomediastinum. We describe the findings in the xray and CT scan of the thorax in a patient diagnosed with IPF. The radiography examination by two thoracic specialist radiologists revealed evidenced extravascular air in the thorax. Disnea, disphagia, aphonia, thoracic pain were the most concerning symptom pre-sented in the patient. The thoracic radiology display air in the pleural cavity along bilateral pneumothorax and pneumomedi-astinum. The patient died 22 days after the start of clinical deterioration due to respiratory failure. KEYWORDS: Pneumothorax, Pneumomediastinum, Idiopathic pulmonary fibrosis. TECHNICAL NOTE Positive assessment of drugs: May, June and July 2018 Pérez Morán MªJ., Cabanes Mariscal MªÁ., Aparicio Hernández R., García Luque A. 236 SUMMARY: The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in May, June and July of 2018, and considered of interest to the healthcare professional, are reviewed here. These are positive technical reports prior to the authorization and placing on the market of the product. KEYWORDS: Abemaciclib (Verzenios®), Adalumumab (Halimatoz®, Hefiya®, Hyrimoz® Hulio®) Binimetinib (Mek-tovi ®), Caplacizumab (Cablivi®), Durvalumab (Imfinzi®), Encorafenib (Braftovi®) Erenumab ( Aimovig®), Eravaciclina (Xevara®), Inotersen (Tegsedi®) ,Lesinurad/alopurinol (Duzallo®), Melatonina(slenyto®), Metreleptina (Myaleota®), Ne-
RSM_74-4
To see the actual publication please follow the link above